Second HER-2 breast cancer test gets US approval
This article was originally published in Clinica
Executive Summary
The US FDA last week approved Ventana Medical Systems' Pathway test as an aid in identifying which breast cancer patients would benefit from treatment with Genentech's Herceptin (trastuzumab) therapy. The test has been a long time coming, but its arrival means that US oncologists will now have double the gene test armoury with which to assess the likely response to Herceptin therapy in patients with breast cancer, a condition that strikes over 180,000 women in the US every year.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.